Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results is drawing significant interest across the industry.
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for ataciceptwith Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Stop spending: 7 purchases people regret the most
- The 50: Ridhi Dogra discusses her bond with Siwet Tomar with Yuvika Choudhary; says 'My last 2
- Report: Brandon Aubrey is seeking $10 million per season
- EU slammed as study reveals climate-harming beef and lamb get 580 times more subsidies than legumes
Source: Original →